Products for administering an initial high dose of Cetrorelix an

Details Products for administering an initial high dose of Cetrorelix an Products for administering an initial high dose of Cetrorelix an

1994-12-08

1997-09-02

Russel, Jeffrey E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514800, A61K 3809

Patent

active

056631456

ABSTRACT:
For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of Cetrorelix acetate and one or more maintenance doses of Cetrorelix acetate, Cetrorelix embonate or a slow-release form of Cetrorelix, is used as a combination preparation for treatment to be administered at specific time intervals.

REFERENCES:
patent: 4305502 (1981-12-01), Gregory et al.
patent: 4569927 (1986-02-01), Rivier et al.
patent: 4817819 (1989-04-01), Kelly et al.
patent: 5046618 (1991-09-01), Wood
patent: 5064813 (1991-11-01), Labrie
patent: 5116818 (1992-05-01), Hodgen et al.
patent: 5171835 (1992-12-01), Janaky et al.
patent: 5480868 (1996-01-01), Kamei et al.
J. Clin. Endo. Metab., vol. 75, No. 2, issued 1992, Behre et al, "Effective Suppression of Luteinizing Hormone . . . ", pp. 393-398.
PNAS USA, vol. 87, issued Sep. 1990, Bokser et al, "Prolonged inhibition of luteinizing hormone . . . ", pp. 7100-7104.
Search Report dated Feb. 7, 1995.
Austria-Codex, Fachinformation 1993/94, A-F, p. 808.
Austria-Codex, Fachinformation 1993/94, G-Q, pp. 2144-2147.
Austria-Codex, Fachinformation 1993/94, R-Z, pp. 3530, 3531, 3544-3549.
Proceedings Of The National Academy of Sciences of the United States of America, Jan. 1, 1991, vol. 88, No. 1, entitled "Inhibition . . . SB-75", pp. 844-848.
Decapeptyl Controlled Release in prostate cancer, pp. 6-26 (not dated).
Released, Asta Pharma, Report dated Sep. 19, 1990, Project No. D-20761, Report No. D-20761/2400000010 (internal) Title "Treatment of DMBA-induced mammary carcinomas . . . D-20761", pp. A-15.
Proc. Natl. Acad. Sci. USA, entitled "Inhibition of growth . . . SB-75" by Korkut, et al., Vo. 88, pp. 844-848, Feb. 1991.
Amtsblatt EPA/Official Journal EPO/Journal Officiel OEB, Sep. 1993, pp. 372-378.
Zoladex in prostate cancer, A real alternative to standard endocrine therapy, pp. 1-35. (1988).
Search Report dated Aug. 1, 1994.
Article, W.Pschyrembel Klinisches Worterbuch, Berlin, 1982, pp. 231, 333, 555.

Affiliated with

Also associated with

Rating

Products for administering an initial high dose of Cetrorelix an does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Products for administering an initial high dose of Cetrorelix an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Products for administering an initial high dose of Cetrorelix an will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-308092